Necrostatin-1 (Nec-1) is a RIP1-targeted inhibitor of necroptosis, a form of programmed cell death discovered and investigated in recent years. There are already many studies demonstrating the essential role of necroptosis in various diseases, including inflammatory diseases, cardiovascular diseases and neurological diseases. However, the potential of Nec-1 in diseases has not received much attention. Nec-1 is able to inhibit necroptosis signaling pathway and thus ameliorate necroptotic cell death in disease development. Recent research findings indicate that Nec-1 could be applied in several types of diseases to alleviate disease development or improve prognosis. Moreover, we predict that Nec-1 has the potential to protect against the complications of coronavirus disease 2019 (COVID-19). This review summarized the effect of Nec-1 in disease models and the underlying molecular mechanism, providing research evidence for its future application.

Necrostatin-1（Nec-1）是针对RIP1的坏死病抑制剂，是近年来发现和研究的程序性细胞死亡形式。已经有许多研究证明坏死病在各种疾病中的重要作用，包括炎性疾病，心血管疾病和神经系统疾病。但是，Nec-1在疾病中的潜力尚未引起足够的重视。Nec-1能够抑制坏死病信号通路，从而改善疾病发展中的坏死性细胞死亡。最近的研究发现表明，Nec-1可用于多种类型的疾病，以减轻疾病的发展或改善预后。此外，我们预测Nec-1有潜力预防2019年冠状病毒疾病（COVID-19）的并发症。